Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Wang

Showing results (111-120 of 167) with videos related to

Pageof 17
Sort By:
The Oncologist|November 25, 2022
Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic AdenocarcinomaPatrick M Grierson, Benjamin Tan, Katrina S Pedersen, et al.
Journal for Immunotherapy of Cancer|October 31, 2023
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumorsRom Leidner, Kevin Conlon, Douglas G McNeel, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 7, 2011
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosisMichael R McClung, Steven Boonen, Ove Törring, et al.
JAMA Oncology|January 21, 2021
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical TrialDavendra P S Sohal, Mai Duong, Syed A Ahmad, et al.
Nature Medicine|July 5, 2016
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapyHong Jiang, Samarth Hegde, Brett L Knolhoff, et al.
Annals of Surgery|August 3, 2020
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal AdenocarcinomaSyed A Ahmad, Mai Duong, Davendra P S Sohal, et al.
Radiology|November 15, 2016
PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human StudiesLoren S Michel, Samantha Dyroff, Frank J Brooks, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|May 11, 2012
Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosisMichael R McClung, Jose R Zanchetta, Arne Høiseth, et al.
The New England Journal of Medicine|August 13, 2009
Denosumab for prevention of fractures in postmenopausal women with osteoporosisSteven R Cummings, Javier San Martin, Michael R McClung, et al.
Menopause (New York, N.Y.)|September 27, 2012
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fractureJames A Simon, Christopher Recknor, Alfred H Moffett, et al.
Pageof 17

Showing results (111-120 of 167) with videos related to

Sort By:
Pageof 17
The Oncologist|November 25, 2022
Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic AdenocarcinomaPatrick M Grierson, Benjamin Tan, Katrina S Pedersen, et al.
Journal for Immunotherapy of Cancer|October 31, 2023
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumorsRom Leidner, Kevin Conlon, Douglas G McNeel, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 7, 2011
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosisMichael R McClung, Steven Boonen, Ove Törring, et al.
JAMA Oncology|January 21, 2021
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical TrialDavendra P S Sohal, Mai Duong, Syed A Ahmad, et al.
Nature Medicine|July 5, 2016
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapyHong Jiang, Samarth Hegde, Brett L Knolhoff, et al.
Annals of Surgery|August 3, 2020
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal AdenocarcinomaSyed A Ahmad, Mai Duong, Davendra P S Sohal, et al.
Radiology|November 15, 2016
PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human StudiesLoren S Michel, Samantha Dyroff, Frank J Brooks, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|May 11, 2012
Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosisMichael R McClung, Jose R Zanchetta, Arne Høiseth, et al.
The New England Journal of Medicine|August 13, 2009
Denosumab for prevention of fractures in postmenopausal women with osteoporosisSteven R Cummings, Javier San Martin, Michael R McClung, et al.
Menopause (New York, N.Y.)|September 27, 2012
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fractureJames A Simon, Christopher Recknor, Alfred H Moffett, et al.
Pageof 17